Inhibiteurs du récepteur de l’IL-6 dans le traitement de la COVID-19 : que savons-nous ?

COVID-19 is a viral infection with predominant respiratory tropism. In its most severe forms, the initial viral aggression leads to acute respiratory failure due to damage secondary to an exacerbated inflammatory response provoked by the activation of innate, followed by adaptive immunity. The infla...

Descripción completa

Detalles Bibliográficos
Autores principales: Lefèvre, C., Plocque, A., Tran, M., Creux, M., Philippart, F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SPLF. Published by Elsevier Masson SAS. 2023
Materias:
Revue Générale
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9791331/
https://www.ncbi.nlm.nih.gov/pubmed/36577608
http://dx.doi.org/10.1016/j.rmr.2022.11.085
Descripción
Sumario:COVID-19 is a viral infection with predominant respiratory tropism. In its most severe forms, the initial viral aggression leads to acute respiratory failure due to damage secondary to an exacerbated inflammatory response provoked by the activation of innate, followed by adaptive immunity. The inflammatory response may entail respiratory distress syndrome, if not multivisceral failure and death. IL-6 receptor inhibitors (Tocilizumab and Sarilumab) have been proposed as treatments. Numerous studies have provided new information, which remains heterogeneous and difficult to interpret. This review is aimed at clarifying the potential role of IL-6 receptor inhibitors in severe forms of COVID-19.

Ejemplares similares